eGenesis is a biotechnology startup that operates in the healthcare sector, specifically in the field of organ transplantation. The company's mission is to address the critical shortage of transplantable organs and cells, a problem that affects over 100,000 people in the U.S. alone. To do this, eGenesis is developing genetically engineered porcine kidneys that are compatible with human bodies, a concept they refer to as Human Compatible (HuCo™) organs and cells.

The company's business model revolves around leveraging advanced genetic engineering techniques to create these HuCo™ organs and cells. Once developed, these organs can be transplanted into patients with failing organs, potentially saving their lives and improving their quality of life. The company's primary clients are individuals in need of organ transplants, a demographic that is constantly growing due to the increasing gap between organ demand and supply.

eGenesis generates revenue by selling these genetically engineered organs to healthcare providers who perform the transplants. The company's work is not only potentially life-saving but also financially promising given the high demand for transplantable organs and the limited supply.

In summary, eGenesis is a pioneering biotech startup that is pushing the boundaries of organ transplantation by developing genetically engineered porcine organs that can be transplanted into humans. The company's innovative approach could potentially end the organ shortage crisis and transform the lives of thousands of people waiting for transplants.

Keywords: Biotechnology, Healthcare, Organ Transplantation, Genetic Engineering, Porcine Organs, Human Compatible Organs, Organ Shortage, Life-saving, High Demand, Innovative.